Program
GENSCI048
A development code. Also written as “GenSci048”.
Its studies are mostly in Uveitis · Endometriosis · Arthritis, Rheumatoid, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 33 open or running | phase 2since Nov 13, 2023 | Nov 13, 2023 | Dec 14, 2027phase 2 · NCT07547995 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2023First study: phase 2 study in Systemic Sclerosis Associated Interstitial Lung DiseaseFirst studyNCT06189495 · 30 planned · China
- Apr 28, 2025Phase 2 study in Endometriosis-related PainNCT06963177 · 200 planned · China
- Apr 14, 2026Phase 2 study in UveitisNCT07547995 · 74 planned · China
Ahead
- Dec 14, 2027Primary completion: phase 2 study in UveitisNCT07547995
- May 15, 2028Primary completion: phase 2 study in Endometriosis-related PainNCT06963177
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07547995Uveitis · China | 2 | Recruiting | Dec 14, 2027 | 74 |
| NCT06963177Endometriosis-related Pain · China | 2 | Recruiting | May 15, 2028 | 200 |
| NCT06189495Systemic Sclerosis Associated Interstitial Lung Disease · China | 2 | Recruiting | Mar 31, 2026 | 30 |
How it is read
Names in the registry
- “GenSci048”, 3 entries
Codes read as this program: GENSCI048.
Conditions, from the studies’ own filings
- Uveitis, 1 study
- Endometriosis, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.